Roche Tecentriq did not reach the main endpoint of triple negative breast cancer research.

Roche announced today that Phase III Clinical Trials (IMpassion 131) of the anti-PD-L1 antibody Tecentriq (atezolizumab) in association with yew alcohol to treat metastatic triple negative breast cancer (TNBC) have failed to significantly improve progression-free survival (PFS).
patients were all PD-L1-positive.
said it was discussing the full results of the Ampassion 131 trial with global health authorities.
the study randomly assigned 651 patients with untreated, insopathic, partially advanced or metastatic TNBC patients who received Tecentriq or a placebo and were used in a joint use with yew alcohol.
the main endpoint of the trial was PFS in the PD-L1-positive population, while the secondary targets included the overall survival rate (OS), overall remission rate (ORR) and mitigation duration of the PD-L1-positive population and the intended treatment population.
roche noted that while the OS data was not yet mature at the time of the analysis, the drugmaker said it planned to continue OS follow-up until a final analysis was carried out.
The results highlight the need for a better understanding of the interactions between cancer and the immune system, including chemotherapy and related therapies," said Levi Garraway, head of global product development at Roche.
In a previous IMpassion 130 study, Tecentriq's joint use with Bristol Myers Squibb's nab-paclitaxel showed significant PFS benefits and significant improvements in OS in PD-L1-positive metastasis TNBC patients.
.